Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein TranslationBOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa...
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to...
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the...
KELOWNA, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single...
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo...
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
WOBURN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today that President...
DENVER, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM; TSXV: IOM), a provider...
Premier gathering expected to host more than 1,200 physicians with 500 virtual participants is the first in-person dermatology medical conference...
Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036NEWTON, Mass. and...
ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of...
SINGAPORE, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today...
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company...
Accomplished Senior Executive with Nearly 30 Years of Sales Experience Spanning CDMO Offerings, Clinical Development Services and Scientific ProductsTUSTIN, Calif.,...
Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on Tuesday, October 12,...
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced...
Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over...
The Regulatory affairs and CRO will oversee the Company’s efforts to secure an IND review of MEAI as a potential...
Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol “SNCE”Business combination will provide Science 37...
